Cardiovasc Diabetol
-
Cardiovasc Diabetol · May 2015
Meta AnalysisCardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM). ⋯ Linagliptin is not associated with increased CV risk versus pooled active comparators or placebo in patients with T2DM.